Oral TREM2 Agonist Shows Safety and Early Signals in Alzheimer’s Phase I Trial

One of the hallmarks of Alzheimer’s disease is the build‑up of amyloid‑β plaques outside neurons. Current therapies that target amyloid‑β have shown only modest benefit, prompting researchers to look elsewhere. Recent work has turned to the brain’s resident immune cells, microglia, which help clear debris and maintain neural networks. A new small‑molecule drug that activates microglial TREM2 is being tested for safety and efficacy.

Preclinical Results in Mice

The drug, named VG‑3927, is an oral compound that can cross the blood‑brain barrier and bind the transmembrane domain of TREM2 and its adaptor DAP12. In cell cultures of human neurons, microglia, and astrocytes, VG‑3927 lowered inflammatory cytokines and markers of neuronal damage. In a transgenic mouse model carrying the common human TREM2 variant, VG‑3909 (another compound in the same class) triggered a neuroprotective gene program in microglia, boosted phagocytosis of amyloid‑β, and increased brain glucose metabolism.

In a first‑in‑human, randomized, double‑blind, placebo‑controlled Phase I trial (NCT06343636) that enrolled 115 participants, VG‑3927 was well tolerated at single and multiple ascending doses up to 140 mg. The drug reached the central nervous system and lowered cerebrospinal fluid levels of soluble TREM2, a biomarker of receptor activation. These safety and pharmacodynamic results support further study of this new class of microglia‑targeting small molecules for Alzheimer’s disease.